51 results about "Vancomycinum" patented technology

The invention provides a novel enterococcus strain Enterococcus qinghaiensis SCFF543 and an anti-oxidation application of the novel enterococcus strain Enterococcus qinghaiensis SCFF543, and belongs to the technical field of microorganisms. Wherein the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on June 10, 2025, and the preservation number is CGMCC No.34843. The invention further discloses a preparation method of the strain. The strain is separated from homemade casein of herdsman families in Demaoha City in Haixi, Qinghai province, has the advantages of strong antioxidant capacity, no vancomycin resistance, strong adhesiveness and the like, and can be suitable for preparing probiotic products with antioxidant effects.

The invention discloses a vancomycin antibacterial effect prediction method based on multivariate analysis, and relates to the technical field of medical data analysis and prediction.The vancomycin antibacterial effect prediction method comprises the steps that S1, prediction data of a target patient is collected, the prediction data comprises static baseline data acquired at the beginning of treatment and dynamic time sequence data acquired at a preset time interval in the treatment process; and S2, preprocessing the prediction data, wherein the preprocessing comprises performing data cleaning on missing values and abnormal values in the static baseline data and the dynamic time sequence data. According to the method, the static baseline data at the beginning of the treatment and the dynamic time sequence data in the treatment process are fused, and the time sequence evolution rule of the dynamic index is captured by using the long and short-term memory network, so that the treatment failure probability and the kidney injury risk probability are dynamically predicted. Meanwhile, supervised learning samples are generated through a sliding window, targeted data preprocessing and risk early warning and trend chart visualization are carried out, the prediction result can be updated in real time, and the prediction precision is improved.

The invention discloses a culture medium for identifying gardnerella vaginalis, and relates to the technical field of bacterial culture media, the key points of the technical scheme are as follows: the culture medium comprises the following raw material components by concentration: 10.0 g / L of casein pancreatin digest, 3.0 g / L of cardiac pancreatin digest, 5.0 g / L of yeast extract powder, 1.0 g / L of corn starch, 5.0 g / L of sodium chloride and 13.0 g / L of agar, and the final concentration of defiberized sheep blood is 5%. The pharmaceutical composition is prepared from 1 mg / mL of sodium alginate, 1 mg / mL of sodium alginate, 1 mg / mL of polyanethole Sulfonate (SPS) and 10 [mu] g / mL of vancomycin. According to the invention, through optimal combination of specific components and dosages thereof, rapid identification and screening of gardnerella vaginalis can be realized, and the method has the advantages of accurate result, strong specificity and the like, and has practical popularization and application values.

This application relates to the field of tumor treatment technology, specifically to a drug combination and evaluation method for improving the sensitivity of MSS CRC to anti-PD-1 / PD-L1 therapy. The drug combination comprises vancomycin and an immune checkpoint inhibitor. Vancomycin is used to remodel the gut microbiota and reduce L-asparagine levels; the immune checkpoint inhibitor is used to activate CD8. + T-cell anti-tumor response. By combining vancomycin with immune checkpoint inhibitors, the antigen-presenting capacity of dendritic cells is enhanced, thereby increasing the sensitivity of MSS CRC to anti-PD-1 or anti-PD-L1 immunotherapy. This application focuses on the upstream initiation link of gut microbiota-metabolites-dendritic cells-immune activation, relieving the inhibition of dendritic cell antigen presentation by L-asparagine and enhancing CD8+. + T cell activation and tumor immune response enhance the sensitivity of MSS-type colorectal cancer to anti-PD-1 / PD-L1 therapy.

A dynamic antimicrobial hydrogel based on natural receptor-ligand recognition, and a preparation method and use thereof are provided. A ligand vancomycin and a receptor AA-based material each are first modified with a modification material, and then a photoinitiator is added to prepare a hydrogel material under irradiation of ultraviolet (UV) light. In the hydrogel, a three-dimensional (3D) network structure is formed through crosslinking. After undergoing a fracture under an external pressure, the hydrogel can rapidly heal itself through crosslinking due to a ligand-receptor interaction and a multi-hydrogen-bond interaction, which bio-mimicks a natural ligand-receptor interaction to realize the dynamics of the hydrogel material. The high antiomicrobial activity of vancomycin imparts the functionality of the hydrogel material; and the physiologically-derived monomer improves the biocompatibility and reduces the biological toxicity.

The invention discloses a blue fluorescent carbon dot as well as a preparation method and application thereof, and belongs to the technical field of drug monitoring. The carbon dot is a boron-nitrogen co-doped carbon dot, a carbon source is citric acid, a nitrogen source is p-phenylenediamine, and a dopant is boric acid; wherein the mass ratio of the citric acid to the boric acid to the p-phenylenediamine is (10-13): (12-15): (11-14). The preparation method comprises the following steps: mixing citric acid, boric acid and p-phenylenediamine, adding ethanol, carrying out ultrasonic treatment, heating at 150-200 DEG C for 20-60 minutes, cooling to room temperature, and purifying and drying supernate to obtain the blue fluorescent carbon dots. The blue fluorescent carbon dot provided by the invention is simple in preparation method, easily available in raw materials and suitable for industrial production, and the prepared fluorescent carbon dot can be used for drug monitoring of vancomycin and is also suitable for detecting ofloxacin and / or levofloxacin in food.

This invention discloses a method for isolating and extracting *Havnia vesicularis* using penicillin and vancomycin. The method mainly includes the following steps: inclusion and screening of patients with bipolar disorder; collection and processing of feces from these patients; isolation and treatment of *Havnia vesicularis* by adding penicillin and vancomycin to the feces; and identification of *Havnia vesicularis*. This invention improves the isolation efficiency and success rate of *Havnia vesicularis*, solving the problems of low isolation efficiency and poor identification accuracy in existing technologies.

The invention provides an anti-biofilm composition based on the synergistic effect of amino fullerene and vancomycin and application of the anti-biofilm composition. The mass ratio of the amino fullerene to the vancomycin is 10: 1. The amino fullerene derivative and vancomycin are combined to have a remarkable synergistic effect in the aspect of inhibiting the formation of the biological membrane for the first time, and the inhibition rate of the biological membrane reaches 93%, so that the amino fullerene derivative and vancomycin have a strong synergistic effect. The composition provided by the invention can effectively remove more than 40% of formed mature biological membranes (24-48-hour biological membranes), which is an effect which cannot be realized by independent use of vancomycin.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The invention discloses a method for performing gene editing in amycolatopsis orientalis. The method comprises the following steps: (1) constructing upstream and downstream homologous arm fragments nrps8-arm-A and nrps8-arm-Z of a target gene nrps8 sequence for DNA repair after knockout; (2) constructing a DNA (Deoxyribose Nucleic Acid) recombinant fragment gDNA-nrps8 capable of coding the sgRNA; (3) constructing a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 editing plasmid pLYCS01; and (4) electrically transforming the pLYCS01 and the gDNA (deoxyribonucleic acid)-nrps8 into the A.keratiniphila cell, so as to obtain the A.keratiniphila cell. The invention also discloses an application of the nrps8 gene of the A. keratiniphila as a gene knockout target of CRISPR / Cas9 (clustered regularly interspaced short palindromic repeats / CRISPR associated protein 9) in the preparation of vancomycin.

The application relates to a kind of nanocomposites, comprising: carrier;Silver;Vancomycin (Van);And hemin chloride (Hemin);Wherein, the silver, vancomycin (Van) and hemin chloride (Hemin) are loaded on carrier;Wherein the nanocomposite releases silver ion, vancomycin and hemin chloride under near infrared light irradiation.The nanocomposite of the application uses nanomaterial as carrier, and can achieve the purpose of high-efficiency sterilization by the loading of silver combined with Van in hollow cavity.At the same time, hemin chloride can realize photo-thermal conversion in cooperation with silver, and effectively remove redundant active oxygen.The successful implementation of the nanocomposite will lay a foundation for constructing efficient and safe antibacterial strategy and provide a new idea for pathogen infection treatment.

The invention provides a method for removing pigments in vancomycin hydrochloride, which comprises the following steps: adjusting the pH value of a vancomycin hydrochloride crude product solution containing pigments to be acidic to obtain a pretreatment feed liquid; carrying out first elution on the pretreated material liquid in a decolorizing column filled with decolorizing resin to obtain an eluent; collecting the eluent and concentrating to obtain a decolorized vancomycin hydrochloride concentrated solution; carrying out a precipitation process on the concentrated solution to obtain a decolorized vancomycin product; wherein the decolorizing resin is selected from at least one of non-polar adsorption resin, ion exchange resin and silica gel filler. According to the method, the pigment in the vancomycin hydrochloride fermentation liquor can be efficiently removed, the absorbance A450nm of the obtained decolorized vancomycin product is greatly reduced, the decolorization yield is high, the loss rate is low, and the removal efficiency of the pigment is greatly improved. In addition, the method can realize repeated utilization of the decolorizing resin, and is more practical and environment-friendly.

The invention belongs to the technical field of chemical drugs, and particularly relates to application of a traditional Chinese medicine composition in preparation of drugs for treating recurrent clostridium difficile infection.The traditional Chinese medicine composition is prepared from 10-50 g of fresh ginger, 3-20 g of honey-fried licorice roots, 5-30 g of ginseng, 3-20 g of dried ginger, 3-30 g of scutellaria baicalensis, 3-30 g of pinellia ternate, 3-15 g of coptis chinensis and 10-30 g of Chinese dates. The traditional Chinese medicine composition is excellent in clinical effect, and in sample research on high-risk crowds such as old people and immunosuppression CDI relapse patients, the treatment scheme of the vancomycin combined with the ginger heart-fire purging decoction is remarkably superior to vancomycin single-drug treatment in the aspect of continuous clinical response rate at the main curative effect end point. This benefit is achieved mainly by reducing the recurrence rate of CDI by more than 60%. The combined scheme shows a robust curative effect in key subgroups such as the elderly and immunosuppressive subgroups, is good in safety, does not increase extra adverse event risks, and particularly does not observe renal function impairment.

The invention provides a vancomycin hydrochloride-containing pharmaceutical composition and a preparation method thereof, the pharmaceutical composition is prepared from vancomycin hydrochloride, PEG6000 and DL-alpha-tocopherol, nitrogen is continuously introduced in the preparation process of the pharmaceutical composition, the whole pharmaceutical composition has simple auxiliary materials and only two auxiliary materials, and the prepared pharmaceutical composition has low content of related substances and is suitable for clinical application. The vancomycin hydrochloride hard capsule is simple in preparation method, high in stability and low in cost, DL-alpha-tocopherol is adopted as an auxiliary material, the prepared vancomycin hydrochloride hard capsule reduces degradation and oxidation of vancomycin hydrochloride, the problem that vancomycin hydrochloride is poor in stability is solved, and the whole preparation method is simple, convenient to operate and suitable for industrial large-scale production.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

The invention discloses a fixing material for a medical device implant and a preparation method of the fixing material. The fixing material comprises a degradable polymer base material with a porous structure and a drug sustained-release coating uniformly loaded on the degradable polymer base material, holes in the degradable polymer are uniformly distributed in a staggered array manner, the holes are circular, the aperture of each hole is 0.5-3.0 mm, and the distance between every two adjacent holes is 0.5-3.0 mm; the drug sustained-release coating contains antibiotics; the antibiotics comprise rifampicin, minocycline hydrochloride, vancomycin, tobramycin, gentamicin and the like. The fixing material disclosed by the invention takes the degradable polymer as a base material, and the drug-loading coating containing antibiotics and anti-inflammatory substances is loaded on the surface, so that slow release of antibiotic drugs can be realized, and the fixing material has excellent antibacterial and anti-inflammatory performance and complete absorbability in a biological environment; and the problems of biocompatibility, infection risk and secondary operation removal of the implant for a long time are solved.

This invention belongs to the field of antibacterial chemical drug technology, specifically relating to a resorcinol compound, its preparation method, and its application. Using resorcinol as the parent core, this invention introduces acyl side chains with different substituents at the 2 and 4 positions of the benzene ring of resorcinol, designing and synthesizing resorcinol compounds with novel structures. Experiments have demonstrated that these resorcinol compounds exhibit significant antibacterial activity against Gram-positive bacteria. Some of these compounds achieve antibacterial effects that are 2 to 4 times stronger than the positive control drug vancomycin. They can be used as novel antibacterial drugs to treat diseases caused by drug-resistant bacteria, possessing significant medicinal value and broad application prospects.

The application discloses a method for efficiently preparing lignin nanoparticles with a hollow structure and application thereof, and belongs to the technical field of material grading and purification. The method comprises the following steps: lignin is prepared into a nanoparticle suspension through a reverse solvent precipitation method, and the prepared lignin nanoparticle suspension is graded by controlling a centrifugal speed, so that the lignin nanoparticles with the hollow structure are obtained. The method has the advantages of simple operation, short time consumption, high efficiency, green environmental protection, low cost and easy industrial production. Meanwhile, vancomycin can be loaded by adding the vancomycin in a self-assembly process, so that a new idea is provided for high-value utilization of lignin.

A medicinal eye drop formulation comprising 10 mg / mL (±5%) to 25 mg / mL (±5%) Vancomycin hydrochloride or, in each case, an equivalent amount of Vancomycin free base or an equivalent amount of an alternative salt of Vancomycin, Tryptophan, Mannitol and Methylcellulose for use in treating eye infection in a human subject.

The invention relates to the technical field of medical monitoring, in particular to a risk assessment method and system for vancomycin-related acute kidney injury, and the method comprises the steps: collecting clinical data of a patient receiving vancomycin treatment, carrying out grading labeling, and dividing the clinical data into a training set and a test set; performing data expansion on the training set sample by adopting a conditional generative adversarial network to obtain an expanded training set; performing feature screening on the extended training set to obtain a screened feature set; constructing a multi-classification integration model based on the screened feature set, obtaining the multi-classification integration model, and outputting a classification prediction result; and performing interpretability analysis on the prediction result of the multi-classification integration model by adopting an SHAP method, calculating the contribution value of each feature to the prediction result, and generating an evaluation report. According to the risk assessment method provided by the invention, the transparency of a model decision process is realized while the prediction accuracy is ensured, and the scientificity and practicability of AKI risk management in vancomycin treatment are effectively improved.

The invention relates to the technical field of antibacterial materials, in particular to an antibacterial nano composite material and a preparation method thereof. The method comprises the following steps: mixing a cerium source solution and an organic ligand solution for reaction, and adding a buffer solution after the reaction is finished to obtain a cerium metal organic framework; mixing the cerium metal organic framework and vancomycin, and reacting to obtain a composite material; a substrate is soaked in a solution containing a coupling agent and a composite material, and the antibacterial nano composite material is formed on the surface of the substrate through deposition. Through the synergistic effect of the cerium metal organic framework and vancomycin, common pathogenic bacteria can be efficiently inhibited. As a carrier, the organic framework can realize slow release of vancomycin, so that the antibacterial action time is prolonged, and the antibacterial effect reduction caused by too fast release of vancomycin in a short time is also avoided. In addition, the antibacterial nano composite material has good biological safety and corrosion resistance.

The invention relates to the field of biotechnology, medicine and cosmetology, and more particularly to a hybrid matrix for use as a biological graft in the preparation of cardiac prostheses. The technical result of the invention includes improving the surface biocompatibility and the stability and durability of a biological graft which provides an antimicrobial response, and also preventing calcification. A method for producing a hybrid biomatrix comprises the following steps: pre-purifying a base of a biomatrix for 0.75-6 hours in two stages, consisting in the decellularization of xenopericardium in a 2-5 wt% water-alcohol solution of Tween-80, saturated with CO2, at a temperature of 20-400°C and a pressure of 10-30 MPa, and the subsequent decellularization of the xenopericardium in a multi-component system containing a solution based on supercritical CO2 and a 1-1.5 vol% addition of a 2-5 wt% water-alcohol solution of Tween-80, at a temperature of 20-400°C and a pressure of 10-30 MPa; stabilizing the biomatrix base by treatment with a 0.1-0.5 wt% aqueous buffer solution of genipin having a pH of 6.0-7.4 for 3-4 hours; and applying to the pre-purified biomatrix base a coating consisting of an aqueous solution of chitosan nanoparticles with an antimicrobial doping additive in the form of silver or vancomycin nanoparticles in a carbonic acid solution, at a pressure of 20-30 MPa and a temperature of 23-270°C for 1-6 hours.

Provided are antibacterial phages that selectively kill bacteria having a resistance gene or the like. Antibacterial phage for this includes CRISPR-Cas13a with a target sequence that recognizes a specific gene as a target. This target sequence is designed as a spacer sequence for crRNA of 14-28 bases. Specific genes are drug resistance genes and toxins. The drug resistance genes are included in bacterial genomes and / or plasmids having one or any combination of the group including: methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, penicillin-resistant pneumococcus, multidrug-resistant Pseudomonas aeruginosa, multidrug-resistant Pseudomonas aeruginosa, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant cephalosporins, third-generation cephalosporin-resistant Pseudomonas aeruginosa, third-generation cephalosporin-resistant E. coli, and fluoroquinolone-resistant E. coli.

The invention provides a method for removing N-nitroso-vancomycin in vancomycin hydrochloride, and relates to the technical field of medicine quality control. The removal method comprises the following steps: carrying out first mixing on a first filler and a first solvent to obtain a first solid-liquid mixture; performing first filtration on the first solid-liquid mixture, and collecting a first solid phase; carrying out second mixing on vancomycin hydrochloride to be treated and a second solvent to obtain a first solution; adjusting the pH value of the first solution to enable the first solution to be acidic to obtain a second solution; performing third mixing on the first solid phase and the second solution to obtain a second solid-liquid mixture; performing secondary filtration on the second solid-liquid mixture, and collecting a liquid phase, namely vancomycin hydrochloride product liquid; wherein the first filler is a reverse-phase filler. By utilizing the removal method, the N-nitroso-vancomycin is removed to the maximum extent, so that the concentration of the N-nitroso-vancomycin in the vancomycin hydrochloride is stably and effectively reduced.

The invention discloses antibiotic bioactive glass and a preparation method thereof, and belongs to the technical field of bioactive glass, the antibiotic bioactive glass comprises the following raw materials by weight: 10-20 parts of bioactive glass powder; 5 to 15 parts of chitosan; 1 to 5 parts of lidocaine hydrochloride; 0.5 to 3 parts of vancomycin; 60-150 parts of a 1% acetic acid aqueous solution; 3-8 parts of a sodium tripolyphosphate solution; the invention aims to solve the problems of weak interface bonding force, difficult antibiotic release control and single function of the traditional material, and by introducing the phosphosilane strontium as an interface molecule, the two-phase interface bonding force is enhanced, the structural integrity and mechanical properties of the material are improved, the osteogenic differentiation is promoted, and the osteoclast activity is inhibited. The material is loaded with vancomycin and lidocaine at the same time, provides antibacterial and analgesic functions, has synergistic anti-infection, analgesic and bone repair capabilities, and is suitable for bone defect repair.

The invention belongs to the technical field of microbial infection treatment and medicine preparation, and discloses various applications of trans-cinnamyl aldehyde in resistance to enterococcus faecalis infection, a related pharmaceutical composition and a treatment method. It is found for the first time that trans-cinnamyl aldehyde has a remarkable inhibition effect on enterococcus faecalis, can destroy a biological membrane of the enterococcus faecalis and promote intestinal mucosa repair after enterococcus faecalis infection, and can selectively inhibit enterococcus faecalis without destroying intestinal probiotics such as lactobacillus and bifidobacterium. The invention also provides a pharmaceutical composition containing trans-cinnamyl aldehyde, and the composition is suitable for pediatric patients to treat intestinal enterococcus faecalis infection for a long time and can reverse the drug resistance of enterococcus faecalis to vancomycin. In addition, the problems that in existing enterococcus faecalis infection treatment, vancomycin is resistant to drugs, a biological membrane is difficult to remove, and probiotic balance and pediatric medication safety are affected are solved, and important clinical application value is achieved.

This utility model provides a vancomycin sample pushing device for a mass spectrometer, belonging to the field of sample pushing technology. It includes a shock-absorbing assembly, comprising a support plate mounted on top of a base plate. A fixing groove is slidably disposed on the top of the support plate, and a slot is formed in the middle of the fixing groove. A lifting block is slidably disposed on the fixing groove through the slot. A first lifting plate is disposed at the bottom of the lifting block, and a telescopic rod is disposed at the bottom of the first lifting plate. A fixing ring is disposed at the bottom of the telescopic rod. The support plate on top of the base plate serves as a base support, and its top-slidably connected fixing groove slides into the lifting block through the middle slot, guiding the vertical movement of the lifting block. The first lifting plate at the bottom of the lifting block bears the load and initially disperses stress. The telescopic rod below absorbs vibration energy using its telescopic characteristics, and the bottom fixing ring limits the range of motion of the telescopic rod and further disperses stress, ultimately achieving effective buffering of vibrations during device operation.

This invention belongs to the field of antibacterial materials, specifically relating to a composite antibacterial material modified with vancomycin through magnetically responsive bond grafting. The material comprises a magnetocaloric material, a polymer coated with the magnetocaloric material having free amino and / or hydroxyl groups, and vancomycin grafted onto the polymer via magnetron sputtering linkage residues. The magnetocaloric material is a functional material capable of generating magnetocaloricity under an alternating magnetic field. The magnetron sputtering linkage residues contain magnetically responsive bonds that can break under an alternating magnetic field, and these magnetically responsive bonds are azo bonds. This invention also provides a method for preparing the material and its applications. This invention has found that the composite material, based on the combined control of the components and modification methods, can unexpectedly achieve synergistic effects, thus effectively improving antibacterial activity and antibacterial spectrum. Furthermore, it can achieve magnetron sputtering of vancomycin, thereby achieving a magnetron sputtering attenuation effect.

The application discloses a vancomycin chemiluminescence immunoassay reagent and a preparation and detection method thereof. The immunoreagent developed by using a high-titer anti-vancomycin specific antibody can accurately determine the content of vancomycin in serum and plasma samples. Compared with traditional methods, the vancomycin chemiluminescence immunoassay reagent provided by the application has high sensitivity and strong specificity, and is combined with a chemiluminescence immunoassay analyzer, and has the advantages of simple operation, high throughput, accurate detection results and the like, and has important significance for guiding clinical rational drug use.

The invention discloses a construction method and application of an Eriocheir sinensis gut-brain axis research model, according to the method, metronidazole, neomycin and vancomycin are added to commercial feed according to the mass ratio of 10: 10: 5 g / kg to prepare compound antibiotic feed, and the Eriocheir sinensis is continuously fed for 96 h. According to the method, a standardized research model capable of synchronously and controllably presenting the causal relation of'intestinal flora disturbance-nervous system response 'is constructed in crustacean for the first time. The model is short in construction period, high in stability and high in repeatability, and a key research tool is provided for deeply analyzing the enteric-cerebral axis interaction mechanism of the eriocheir sinensis and even crustacean, screening neural active substances and evaluating neurotoxicity of environmental stress.